用皮奥格利塔修改肌肉代谢失调,包括体肌炎:一个单臂试验
Brittany L Adler1, Michael R Bene2, Cissy Zhang3
1Division of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. brit.adler@jhmi.edu.
Nature communications
|March 15, 2026
概括
作为PPARγ激动剂的皮奥格利塔显示出调节肌肉新陈代谢的潜力,用于包括体肌炎 (IBM) 患者. 一些参与者经历了较慢的功能衰退与有利的代谢反应.
科学领域:
- 肌肉生物学 肌肉生物学
- 代谢途径 代谢途径
- 药理学 药理学是指药理学的学科.
背景情况:
- 包容体肌炎 (IBM) 是一种进展性神经肌肉疾病,治疗选择有限.
- 在IBM患者的肌肉代谢学揭示了显著的代谢异常.
- PPARγ激动剂可能通过准代谢途径提供治疗途径.
研究的目的:
- 为了评估皮奥格利塔对肌肉新陈代谢的影响,包括体肌炎的患者.
- 评估PPARGC1A表达和下游代谢途径的变化.
- 在IBM中探索pioglitazone的初步安全性和有效性.
主要方法:
- 单臂,开放标签的第一阶段临床试验.
- 16周的观察期,然后每天服用45毫克皮奥格利塔32周.
- 主要结果:肌肉PPARGC1A表达和代谢途径的变化;次要结果:临床功能 (IBM-FRS,m-TUG) 和安全性.
主要成果:
- 皮奥格利塔治疗调节了肌肉代谢特征,增加了PPARGC1A的表达,并增强了氧化酸化.
- 临床结果没有总体变化,但具有良好的代谢反应的子组在IBM-FRS和m-TUG.中表现出较慢的下降.
- 副作用包括肌痛和心力衰竭恶化;由于COVID-19,试验提前结束.
结论:
- 皮奥格利塔在IBM中展示了调节肌肉代谢的初步证据.
- 需要进一步的研究,以探索pioglitazone在IBM中的治疗潜力.
- 亚组分析表明,在具有良好的代谢反应的患者中,潜在的益处.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
813
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
813
01:23Dipeptidyl Peptidase 4 Inhibitors
876
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
876